Early replacement of re-induction therapy following failed intensive induction treatment enhances the therapeutic efficacy of newly diagnosed AML.

Jingchen Sui, Zijing Xu, Ludan Zhang, Yu Jiao, Renjie Bian, Deng Pan, Xiaojing Yan

Abstract read

In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jingchen Sui *Department of Hematology, The First Affiliated Hospital of China Medical University, No.155, Nanjing North Street, Heping District, Shenyang, 110001, China.

Zijing Xu *Department of Hematology, The First Affiliated Hospital of China Medical University, No.155, Nanjing North Street, Heping District, Shenyang, 110001, China.

Ludan ZhangDepartment of Hematology, The First Affiliated Hospital of China Medical University, No.155, Nanjing North Street, Heping District, Shenyang, 110001, China.

Yu JiaoDepartment of Hematology, The First Affiliated Hospital of China Medical University, No.155, Nanjing North Street, Heping District, Shenyang, 110001, China.

Renjie BianDepartment of Hematology, The First Affiliated Hospital of China Medical University, No.155, Nanjing North Street, Heping District, Shenyang, 110001, China.

Deng PanDepartment of Hematology, The First Affiliated Hospital of China Medical University, No.155, Nanjing North Street, Heping District, Shenyang, 110001, China. pandengjzz@qq.com.

Xiaojing YanDepartment of Hematology, The First Affiliated Hospital of China Medical University, No.155, Nanjing North Street, Heping District, Shenyang, 110001, China. yanxiaojing_pp@hotmail.com.

Funding

Liaoning Province Central Guidance Special Project for Local Science and Technology Development 2023JH6/100200006Translational Research Grant of HCRCH 2020ZKMB06Xingliao Talents Program xlyc1807265

6 · The paper itself

Abstract

20-30% of newly diagnosed Acute myeloid leukemia(AML) patients fail to achieve complete response (CR) following intensive induction chemotherapy. This retrospective study aimed to evaluate the efficacy of reinduction regimens in improving CR rates among newly diagnosed AML patients who did not achieve partial response(PR) after initial intensive induction therapy. We conducted a retrospective analysis of 175 newly diagnosed AML patients aged 18-60 years, treated at the First Affiliated Hospital of China Medical University between January 2020 and March 2024. Patients who did not achieve PR after first line inductive therapy were switched to alternative intensive chemotherapy regimens or regimens including venetoclax and azacitidine. After the first induction cycle, the overall response rate(ORR) was 82.8%. For patients with no response, early replacement of reinduction regimens, especially those containing venetoclax, led to an ORR of 90.2% after two cycles of induction therapy. We recommend that young patients with newly diagnosed AML be primarily treated with DA/IA induction therapy. For those who fail to achieve remission, early replacement of re-induction therapy enhances the therapeutic efficacy of newly diagnosed young adult AML.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsInduction ChemotherapyLeukemia, Myeloid, AcuteAdolescentAdultAzacitidineBridged Bicyclo Compounds, HeterocyclicFemaleHumansMaleMiddle AgedRemission InductionRetrospective StudiesSulfonamidesTreatment OutcomeYoung AdultAzacitidineBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclax

Identifiers

PMID40481098

DOI10.1038/s41598-025-04139-5

PMCPMC12144250

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.